GlassScriptPhysician profile
Mark Christopher Lawlor
NPI 1043770324
$5,227.02
in general payments reported to CMS, 2019-2025
13 companies · $2,921 in 2025
The $2,921 reported for 2025 was more than what 76% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,306 · 2025: $2,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,767 · Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,766.83 |
| Food and Beverage | $2,460.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $1,034.32 | 2024-2025 | Excelsius Gps, Xlif, Reline |
| Riwospine, INC. | $914.79 | 2024 | Spine |
| Arthrex, INC. | $764.53 | 2025 | |
| Alphatec Spine, INC | $661.18 | 2025 | Other - Miscellaneous |
| Stryker Corporation | $469.25 | 2024 | Monterey Al, Mako |
| Medtronic, INC. | $432.07 | 2024-2025 | Unid_pass |
| Vb Spine LLC | $284.70 | 2025 | Yukon Oct Spinal System |
| Depuy Synthes Sales INC. | $173.09 | 2024-2025 | Trialtis, Teligen |
| Si-Bone, INC. | $135.00 | 2025 | |
| Solventum Corporation | $128.00 | 2024 | Prevena, V.A.C. Veraflo |
| Orthofix Medical, INC. | $114.84 | 2024 | Cervical-Stim |
| Cerapedics INC. | $97.88 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Sumitomo Pharma America, INC. | $17.37 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lawlor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.